Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2000-08-16
2001-07-17
Oswecki, Jane C. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S398000, C514S399000, C514S408000, C514S424000, C514S426000, C514S428000, C514S438000, C514S445000, C514S447000, C548S346100, C548S541000, C548S550000, C548S556000, C549S062000, C549S065000, C549S066000, C549S070000, C549S074000, C549S078000, C549S081000
Reexamination Certificate
active
06262101
ABSTRACT:
BACKGROUND OF THE INVENTION
This invention relates to a method of reducing the level of cytokines and their precursors in mammals and to compounds and compositions useful therein. In particular, the invention pertains to a class of compounds which mediate the action of phosphodiesterases, particularly PDE III and PDE IV, and the formation of TNF&agr; and NF&kgr;B.
Tumor necrosis factor alpha, (TNF&agr;) is a cytokine which is released primarily by mononuclear phagocytes in response to immunostimulators. When administered to animals or humans, TNF&agr; can cause inflammation, fever, cardiovascular effects, hemorrhage, coagulation, and acute phase responses similar to those seen during acute infections and shock states.
The nuclear factor &kgr;B (NF&kgr;B) is a pleiotropic transcriptional activator (Lenardo, et al.,
Cell
1989, 58, 227-29) which has been implicated in a variety of disease and inflammatory states. NF&kgr;B is thought to regulate cytokine levels including, but not limited to, TNF&agr; and to be an activator of HIV transcription (Dbaibo et al.,
J. Biol. Chem.
1993, 17762-66; Duh et al.,
Proc. Natl. Acad. Sci.
1989, 86, 5974-78; Bachelerie et al.,
Nature
1991, 350, 709-12; Boswas et al.,
J. Acquired Immune Deficiency Syndrome
1993, 6, 778-786; Suzuki et al.,
Biochem. And Biophys. Res. Comm.
1993, 193, 277-83; Suzuki et al.,
Biochem. And Biophys. Res Comm.
1992, 189, 1709-15; Suzuki et al.,
Biochem. Mol. Bio. Int.
1993, 31(4), 693-700; Shakhov et al. 1990, 171, 35-47; and Staal et al.,
Proc. Natl. Acad. Sci. USA
1990, 87, 9943-47). Thus, inhibition of NF&kgr;B binding can regulate transcription of cytokine gene(s) and through this modulation and other mechanisms be useful in the inhibition of a multitude of disease states. TNF&agr; and NF&kgr;B levels are influenced by a reciprocal feedback loop.
Many cellular functions are mediated by levels of adenosine 3′,5′-cyclic monophosphate (cAMP). Such cellular functions can contribute to inflammatory conditions and diseases including asthma, inflammation, and other conditions (Lowe and Cheng,
Drugs of the Future,
17(9), 799-807, 1992). It has been shown that the elevation of cAMP in inflammatory leukocytes inhibits their activation and the subsequent release of inflammatory mediators, including TNF&agr; and NF&kgr;B. Increased levels of cAMP also leads to the relaxation of airway smooth muscle. The primary cellular mechanism for the inactivation of cAMP is the break-down of cAMP by a family of isoenzymes referred to as cyclic nucleotide phosphodiesterases (PDE), of which seven are known. It is recognized, for example, that the inhibition of PDE type IV is particularly effective in both the inhibition of inflammatory mediator release and the relaxation of airway smooth muscle. Thus, compounds which inhibit PDE IV exhibit the desirable inhibition of inflammation and relaxation of airway smooth muscle with a minimum of unwanted side effects, such as cardiovascular or anti-platelet effects. It is now known that inhibition of TNF&agr; production is a consequence of inhibition of PDE IV. L. J. Lombardo,
Current Pharmaceutical design,
1, 255-268 (1995).
Excessive or unregulated TNF&agr; production has been implicated in a number of disease conditions. These include endotoxemia and/or toxic shock syndrome {Tracey et al.,
Nature
330, 662-664 (1987) and Hinshaw et al.,
Circ. Shock
30, 279-292 (1990)}; cachexia {Dezube et al.,
Lancet,
335 (8690), 662 (1990)}; and Adult Respiratory Distress Syndrome (ARDS) where TNF&agr; concentrations in excess of 12,000 pg/milliliters have been detected in pulmonary aspirates from ARDS patients {Millar et al.,
Lancet
2 (8665), 712-714 (1989)}. Systemic infusion of recombinant TNF&agr; also resulted in changes typically seen in ARDS {Ferrai-Baliviera et al.,
Arch Surg.
124(12), 1400-1405 (1989)}.
TNF&agr; also appears to be involved in bone resorption diseases, including arthritis where it has been determined that when activated, leukocytes will produce a bone-resorbing activity, and data suggests that TNF&agr; contributes to this activity {Bertolini et al.,
Nature
319, 516-518 (1986) and Johnson et al.,
Endocrinology
124(3), 1424-1427 (1989)}. It has been determined that TNF&agr; stimulates bone resorption and inhibits bone formation in vitro and in vivo through stimulation of osteoblast formation and activation in combination with inhibition of osteoblast function. Although TNF&agr; may be involved in many bone resorption diseases, including arthritis, the most compelling link with disease is the association between production of TNF&agr; by tumor or host tissues and malignancy associated hypercalcemia {
Calci. Tissue Int.
(
US
) 46 (Suppl.), S3-10 (1990)}. In Graft versus Host Reaction, increased serum TNF&agr; levels have been associated with major complications following acute allogenic bone marrow transplants {Holler et al.,
Blood,
75(4), 1011-1016 (1990)}.
Cerebral malaria is a lethal hyperacute neurological syndrome associated with high blood levels of TNF&agr; and is the most severe complication occurring in malaria patients. Levels of serum TNF&agr; correlated directly with the severity of the disease and the prognosis in patients with acute malaria attacks {Grau et al.,
N. Engl. J. Med.
320 (24), 1586-1591 (1989)}.
Macrophage-induced angiogenesis is known to be mediated by TNF&agr;. Leibovich et al. {
Nature,
329, 630-632 (1987)} showed TNF&agr; induces in vivo capillary blood vessel formation in the rat cornea and the developing chick chorioallantoic membranes at very low doses and suggest TNF&agr; is a candidate for inducing angiogenesis in inflammation, wound repair, and tumor growth. TNF&agr; production also has been associated with cancerous conditions, particularly induced tumors {Ching et al.,
Brit. J. Cancer,
(1955) 72, 339-343, and Koch,
Progress in Medicinal Chemistry,
22, 166-242 (1985)}.
TNF&agr; also appears to play a role in the area of chronic pulmonary inflammatory diseases. The deposition of silica particles leads to silicosis, a disease of progressive respiratory failure caused by a fibrotic reaction. Antibodies to TNF&agr; completely blocked the silica-induced lung fibrosis in mice {Pignet et al.,
Nature,
344:245-247 (1990)}. High levels of TNF&agr; production (in the serum and in isolated macrophages) have been demonstrated in animal models of silica and asbestos induced fibrosis {Bissonnette et al.,
Inflammation
13(3), 329-339 (1989)}. Alveolar macrophages from pulmonary sarcoidosis patients have also been found to spontaneously release massive quantities of TNF&agr; as compared with macrophages from normal donors {Baughman et al.,
J. Lab. Clin. Med.
115 (1), 36-42 (1990)}.
TNF&agr; is also implicated in the inflammatory response which follows reperfusion, called reperfusion injury, and is a major cause of tissue damage after loss of blood flow {Vedder et al.,
PNAS
87, 2643-2646 (1990)}. TNF&agr; also alters the properties of endothelial cells and has various pro-coagulant activities, such as producing an increase in tissue factor pro-coagulant activity and suppression of the anticoagulant protein C pathway as well as down-regulating the expression of thrombomodulin {Sherry et al.,
J. Cell Biol.
107, 1269-1277 (1988)}. TNF&agr; has pro-inflammatory activities which together with its early production (during the initial stage of an inflammatory event) make it a likely mediator of tissue injury in several important disorders including but not limited to, myocardial infarction, stroke and circulatory shock. Of specific importance may be TNF&agr;-induced expression of adhesion molecules, such as intercellular adhesion molecule (ICAM) or endothelial leukocyte adhesion molecule (ELAM) on endothelial cells {Munro et al.,
Am. J. Path.
135 (1), 121-132 (1989)}.
TNF&agr; blockage with monoclonal anti-TNF&agr; antibodies has been shown to be beneficial in
Muller George W.
Shire Mary
Celgene Corporation
Mathews, Collins Shepherd & Gould P.A.
Oswecki Jane C.
LandOfFree
Immunotherapeutic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunotherapeutic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunotherapeutic agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2482896